ProCE Banner Activity

PEACE-1: Overall Survival With Abiraterone With or Without Local Radiotherapy + SoC in de novo Metastatic Castration-Sensitive Prostate Cancer

Slideset Download
Conference Coverage
In this randomized, phase III trial, the addition of abiraterone to ADT plus docetaxel was associated with a significant improvement in rPFS and overall survival in men with de novo metastatic CSPC.

Released: September 27, 2021

Expiration: September 26, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Exelixis, Inc.

Ipsen Biopharmaceuticals Inc